Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, et al. Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach. JNCI: J Natl Cancer Inst. 2020;112:708–19.

Article  PubMed  Google Scholar 

Lu B, Natarajan E, Balaji Raghavendran HR, Markandan UD. Molecular classification, treatment, and genetic biomarkers in triple-negative breast cancer: A review. Technol Cancer Res Treat. 2023;22:15330338221145246.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022;12:919072. https://doi.org/10.3389/fonc.2022.919072.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70. https://doi.org/10.1158/2326-6066.CIR-13-0127.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26. https://doi.org/10.1056/NEJMoa2202809.

Article  CAS  PubMed  Google Scholar 

Thomas R, Al-Khadairi G, Decock J. Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects. Front Oncol. 2021;10:600573.

Article  PubMed  PubMed Central  Google Scholar 

Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39. https://doi.org/10.1016/S0140-6736(18)30789-X.

Article  PubMed  Google Scholar 

Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662–80. https://doi.org/10.1038/s41568-020-0285-7.

Article  CAS  PubMed  Google Scholar 

Addissouky TA, El Sayed IET, Ali MM, Wang Y, El Baz A, Khalil AA, et al. Can vaccines stop cancer before it starts? Assessing the promise of prophylactic immunization against high-risk preneoplastic lesions. J Cell Immunol. 2023;5:127–40.

Article  Google Scholar 

Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review. JAMA Oncol. 2016;2:1354–60. https://doi.org/10.1001/jamaoncol.2016.1061.

Article  PubMed  Google Scholar 

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66. https://doi.org/10.1200/JCO.2013.55.0491.

Article  PubMed  PubMed Central  Google Scholar 

Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 2016;8:93–107. https://doi.org/10.2147/BCTT.S69488.

Article  CAS  PubMed  Google Scholar 

Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389:2430–42. https://doi.org/10.1016/S0140-6736(16)32454-0.

Article  CAS  PubMed  Google Scholar 

Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag Res. 2022;14:1–17. https://doi.org/10.2147/CMAR.S316700.

Article  PubMed  PubMed Central  Google Scholar 

Hubalek M, Czech T, Muller H. Biological subtypes of triple-negative breast cancer. Breast Care (Basel). 2017;12:8–14. https://doi.org/10.1159/000455820.

Article  PubMed  Google Scholar 

Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, et al. Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. Eur J Cancer. 2021;142:63–82.

Article  CAS  PubMed  Google Scholar 

Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16:1092–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang CS, Yu AL, Tseng LM, Chow LWC, Hou MF, Hurvitz SA, Schwab RB, L Murray J, Chang HK, Chang HT, Chen SC, Kim SB, Hung JT, Ueng SH, Lee SH, Chen CC, Rugo HS. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. J Immunother Cancer. 2020;8(2):e000342. https://doi.org/10.1136/jitc-2019-000342.

Solinas C, Aiello M, Migliori E, Willard-Gallo K, Emens LA. Breast cancer vaccines: heeding the lessons of the past to guide a path forward. Cancer Treat Rev. 2020;84:101947.

Article  CAS  PubMed  Google Scholar 

Zhu S-Y, Yu K-D. Breast cancer vaccines: disappointing or promising? Front Immunol. 2022;13:828386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeichner SB. The failed Theratope vaccine: 10 years later. J Am Osteopath Assoc. 2012;112:482–3.

PubMed  Google Scholar 

Hamrita B, Rouissi K, Elgaaied AB. Immunoprotemics views: many cancers one goal. Res Rev Biosci. 2011;5(1):50–60.

Dhanushkumar T, Santhosh ME, Selvam PK, Rambabu M, Dasegowda KR, Vasudevan K, Doss CG. Advancements and hurdles in the development of a vaccine for triple-negative breast cancer: a comprehensive review of multiomics and immunomics strategies. Life Sci. 2023;122360. https://doi.org/10.1016/j.lfs.2023.122360.

•• Hosseini M, Seyedpour S, Khodaei B, Loghman A-H, Seyedpour N, Yazdi M-H, et al. Cancer vaccines for triple-negative breast cancer: a systematic review. Vaccines. 2023;11:146. A careful and thorough review of breast cancer vaccines, both in new clinical trials and those recently completed.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020;6:4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasi PM, Kalli K, Block MS, Hobday TJ, Dockter TJ, Suman VJ, Erskine CL, et al. A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer. 2015:e14028. https://doi.org/10.1200/jco.2015.33.15_suppl.e14028.

Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, et al. Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients. Clin Cancer Res. 2018;24:3014–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Budd GT, Johnson JM, Rhoades E, Moore H, Levengood H, Kruse M, et al. Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer. Cancer Res. 2023;83:3035.

Article  Google Scholar 

Tuohy VK, Jaini R, Johnson JM, Loya MG, Wilk D, Downs-Kelly E, et al. Targeted vaccination against human α-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer. Cancers. 2016;8:56.

Article  PubMed  PubMed Central  Google Scholar 

Costa RL, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer. 2020;6:10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, et al. Identification of immunogenic MHC class II human HER3 peptides that mediate anti-HER3 CD4+ Th1 responses and potential use as a cancer vaccine. Cancer Immunol Res. 2022;10:108–25.

Article  CAS  PubMed  Google Scholar 

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial. Clin Cancer Res. 2017;23:2961–71.

Article  CAS  PubMed  Google Scholar 

Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, et al. Ii-Key/HER-2/neu(776–790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother. 2007;56:601–13. https://doi.org/10.1007/s00262-006-0213-z.

Article  CAS  PubMed  Google Scholar 

Olatunji G, Kokori E, Yusuf IA, Akinmoju O, Isarinade T, Komolafe R, et al. AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence. Medicine. 2023;102:e36793. https://doi.org/10.1097/md.0000000000036793.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muscarella P, Bekaii-Saab T, McIntyre K, Rosemurgy A, Ross SB, Richards DA, et al. A phase 2 randomized placebo-controlled adjuvant trial of GI-4000, a recombinant yeast expressing mutated RAS proteins in patients with resected pancreas cancer. J Pancreat Cancer. 2021;7:8–19.

Article  PubMed  PubMed Central  Google Scholar 

Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother. 2014;63:225–34.

Article  CAS  PubMed  Google Scholar 

Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, et al. Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury. Cancer Immunol Res. 2015;3:1248–56.

Article  CAS